Thiazole Derivative PI3K mTOR Inhibitor Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PI3K and mTOR inhibitors face challenges in achieving effective cancer treatment due to toxicity and incomplete inhibition of cancer cell growth and survival pathways.
Innovation Solution
Development of a thiazole derivative with superior PI3K and mTOR inhibitory activity, specifically designed to target cancer cells with minimal toxicity, represented by the compound formula (I) or its pharmaceutically acceptable salts, which inhibits PI3K and mTOR pathways effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current PI3K and mTOR inhibitors are used for cancer treatment, then cancer cell growth and survival pathways are inhibited, but toxicity and incomplete inhibition of cancer cell growth occur
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of inhibitor compounds through systematic variations in molecular composition and configuration. Multiple embodiments present compounds with different substituent groups, ring structures, and molecular weights to optimize the balance between inhibition effectiveness and toxicity profile
Solution Approach 2:
The patent employs composite materials by creating hybrid molecular structures that combine different functional groups and structural motifs within single inhibitor compounds. The described compounds integrate heterocyclic rings, aromatic systems, and various substituent patterns to achieve enhanced selectivity and reduced off-target toxicity
2Productivity
If current PI3K and mTOR inhibitors are used, then some cancer pathways are blocked, but incomplete inhibition of cancer cell growth and survival pathways occurs
Solution Approach 1:
The patent applies universality by designing inhibitor compounds capable of targeting multiple nodes within the PI3K-mTOR signaling pathway simultaneously. The molecular structures are engineered to interact with conserved regions across different kinase isoforms, enabling broad-spectrum inhibition of cancer cell growth, survival, and metabolism pathways
3Reliability
If PI3K pathway is inhibited, then cancer cell growth and survival are suppressed, but selectivity between cancer cells and normal cells becomes challenging
Solution Approach 1:
The patent applies local quality by introducing specific substituent groups and structural features at particular positions within the inhibitor molecules. These localized modifications create steric and electronic properties that enhance binding affinity to cancer-specific mutated forms of PI3K and mTOR while reducing interaction with normal cellular proteins
Data Source
AI summary
The present invention relates to a compound represented by the formula (I) or (I′):wherein each symbol is as defined in the specification, or a salt thereof, and a PI3K and(or) mTOR inhibitor containing the compound or a prodrug thereof.